Concerning safety and efficacy of concurrent and consolidative durvalumab with thoracic radiotherapy in PDL1-unselected stage III non-small cell lung cancer: brief report

Consolidative durvalumab, an anti-programmed death ligand 1 (PDL1) immune checkpoint inhibitor, administered after concurrent chemoradiation improves outcomes of patients with locally advanced non-small cell lung cancer (NSCLC) without substantially increasing toxicities. We studied a chemotherapy-free regimen of thoracic radiotherapy (RT) with concurrent and consolidative durvalumab.